EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Secretoneurin Concentrations Measured with a High-Throughput Assay and Clinical Outcomes in Patients Hospitalized with Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study

Helge Røsjø, Ilde Rugolo, Angelica Gjørven, Arne L Faaren, Frank Frantzen, Geir Christensen, Arne Didrik Høiseth, Anett H Ottesen, Rahul Bhatnagar, Magnus N Lyngbakken, Torbjørn Omland

The Journal of Applied Laboratory Medicine · 2025

DOI: 10.1093/jalm/jfaf011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von Helge Røsjø und 10 weiteren Autor:innen. Beteiligte Einrichtung: Akershus Clinical Research Center (ACR), Division of Research and Innovation, Akershus University Hospital, Lørenskog, Norway. Hauptthemen laut MEDLINE: Dyspnea, Heart Failure, Secretogranin II, High-Throughput Screening Assays. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-throughput assays are required for novel biomarkers to have clinical potential. Secretoneurin (SN) is a candidate biomarker, and the performance of a new high-throughput SN assay is not known.

Methods

We measured SN concentrations with a prototype chemiluminescent immunoassay (CLIA) in 299 patients hospitalized with acute dyspnea. We compared the results with a CE-marked SN enzyme linked immunosorbent assay (ELISA). We adjudicated the cause of dyspnea as heart failure (HF) or non-HF, and we obtained information on all-cause mortality during follow-up.

Results

SN concentrations measured with CLIA and ELISA were closely correlated: rho = 0.81, P < 0.001. SN CLIA concentrations were higher in HF patients (n = 129) compared to patients with non-HF-related dyspnea (n = 170): median 51 (quartile 1–3 40–69) vs 41 (32–54) pmol/L, P < 0.001. The area under the curve (AUC) of SN CLIA to diagnose HF was 0.64 (95% CI, 0.58–0.71) and the AUC of N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 0.85 (0.81–0.89). During median 818 days follow-up, 110 patients died (37%). There was a nonlinear association between SN CLIA concentrations and mortality with optimal cutpoint 53 pmol/L. SN CLIA concentrations >53 pmol/L were associated with mortality after adjusting for clinical variables and NT-proBNP and cardiac troponin T concentrations: hazard ratio 1.7 (95% CI, 1.1–2.7), AUC 0.67 (0.61–0.74). We found similar results for SN ELISA for diagnosis and prognosis with AUC 0.63 (0.57–0.70) for the prediction of mortality.

Conclusion

The high-throughput SN CLIA correlates with the SN ELISA and provides independent prognostic information over established biomarkers in patients with acute dyspnea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyspneaHeart FailureSecretogranin IIHigh-Throughput Screening AssaysHumansFemaleMaleAgedBiomarkersMiddle AgedLuminescent MeasurementsEnzyme-Linked Immunosorbent AssayHospitalizationPrognosisAged, 80 and overNatriuretic Peptide, BrainNeuropeptidesPeptide Fragments

Substanzen

BiomarkerssecretoneurinSecretogranin IIpro-brain natriuretic peptide (1-76)Natriuretic Peptide, BrainNeuropeptidesPeptide Fragments

Autor:innen und Institutionen

  • Akershus Clinical Research Center (ACR), Division of Research and Innovation, Akershus University Hospital, Lørenskog, Norway.
  • K. G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway.
  • Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • CardiNor AS, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Zitieren

APA

Røsjø, H., Rugolo, I., Gjørven, A., Faaren, A. L., Frantzen, F., Christensen, G., Høiseth, A. D., Ottesen, A. H., Bhatnagar, R., Lyngbakken, M. N., & Omland, T. (2025). Secretoneurin Concentrations Measured with a High-Throughput Assay and Clinical Outcomes in Patients Hospitalized with Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf011

Vancouver

Røsjø H, Rugolo I, Gjørven A, Faaren AL, Frantzen F, Christensen G, et al. Secretoneurin Concentrations Measured with a High-Throughput Assay and Clinical Outcomes in Patients Hospitalized with Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfaf011

BibTeX
@article{Rsj2025,
  author = {Røsjø, Helge and Rugolo, Ilde and Gjørven, Angelica and Faaren, Arne L and Frantzen, Frank and Christensen, Geir and Høiseth, Arne Didrik and Ottesen, Anett H and Bhatnagar, Rahul and Lyngbakken, Magnus N and Omland, Torbjørn},
  title = {Secretoneurin Concentrations Measured with a High-Throughput Assay and Clinical Outcomes in Patients Hospitalized with Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2025},
  doi = {10.1093/jalm/jfaf011}
}
Kostenlos starten →